Tag: JNJ
-
KMB Stock Falls After Earnings, but “Value” May be the Key
Kimberly-Clark Corp. (NYSE: KMB) stock is down after its earnings report on Jan. 27. The company was expected to give investors a snapshot of the consumer. It did just that, and the word for KMB stock, as well as many consumer staples stocks this earnings season, may once again be “value.” The company’s fourth-quarter 2025 report showed that its focus…
-
Johnson & Johnson Earnings Power Shifts Into Higher Gear
Johnson & Johnson’s latest earnings report shows a mature healthcare giant acting more like a growth stock again, and investors are taking notice. In Q4 2025, Johnson & Johnson (NYSE: JNJ) delivered 9.1% reported sales growth to 24.6 billion, with operational growth of 7.1% and adjusted operational growth of 6.1%. Numbers like that should be…
-
The Dogs of the Dow for New Year 2026
Every year, one of the best strategies is the Dogs of the Dow. You simply buy a basket of underperformers on the Dow Jones Industrial Average (DJIA) that pay dividends, and sell them by the end of the year. The Strategy Behind the Dogs of the Dow The Dogs of the Dow strategy is made…
-
The Dogs of the Dow: A Year-End Dividend Opportunity
One of the best year-end investment strategies is the Dogs of the Dow. Granted, some analysts say it’s an antiquated strategy with low success rates. But history proves they still have plenty of bite. In fact, having traded the Dogs of the Dow since 2016, I can tell you it’s still a solid strategy with dividend…
-
JNJ Stock Slips Despite Beat and Raised Guidance
Johnson & Johnson delivered another solid quarter, beating expectations on both revenue and earnings while raising full-year guidance. However, the stock slipped in early trading as investors reacted to broader market weakness and an FDA warning for one of the company’s key oncology drugs, Carvykti. Despite the pullback, JNJ stock is up 32% in 2025…